Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in hashimoto thyroiditis from papillary thyroid carcinomas

Endocrine Pathology

Volumn 21, Issue 2, 2010, Pages 73-79

  Sadow, Peter M ^a,d   Heinrich, Michael C ^b   Corless, Christopher L ^b   Fletcher, Jonathan A ^c   Nosé, Vânia ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BRAF; Dominant nodule; Hashimoto thyroiditis; HRAS; KRAS; NRAS; Papillary thyroid carcinoma; RET PTC

Indexed keywords

B RAF KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; K RAS PROTEIN; PARAFFIN; PROTEIN HRAS; PROTEIN NRAS; PROTEIN PATCHED 1; PROTEIN RET; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; CELL SURFACE RECEPTOR; HRAS PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PATCHED RECEPTORS; PROTEIN P21; RAS PROTEIN; RET PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EXON; FEMALE; GENE DELETION; GENE REARRANGEMENT; GENETIC SCREENING; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENTAL FINDING; MALE; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; THYROID NODULE; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME; ADENOCARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; GENOTYPE; MIDDLE AGED; MUTATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID TUMOR;

ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE REARRANGEMENT; GENOTYPE; HASHIMOTO DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS;

EID: 77955873741     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-009-9101-3     Document Type: Article

References (35)

1. Berho M, Suster S. Clear nuclear changes in Hashimoto's thyroiditis. A clinicopathologic study of 12 cases. Ann Clin Lab Sci 25:513-21, 1995.
2. Cassinelli G, Favini E, DeglInnocenti D, et al. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia (New York, NY. 11:10-21, 2009.
3. Corless CL, McGreevey L, Town A, et al. KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. J Mol Diagn. 6:366-70, 2004.
4. Cruz F, 3rd, Rubin BP, Wilson D, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 63:5761-6, 2003.
5. Denning K, Smyth P, Cahill S, et al. ret/PTC-1 expression alters the immunoprofile of thyroid follicular cells. Molecular cancer 7:44, 2008.
6. Giorgadze T, Rossi ED, Fadda G, et al. Does the fine-needle aspiration diagnosis of "Hurthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy? Diagn Cytopathol. 31:307-12, 2004.
7. Isenberg SF. Thyroiditis and thyroid cancer. Otolaryngol Head Neck Surg. 119:403-5, 1998.
8. Kang DY, Kim KH, Kim JM, et al. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population. Thyroid. 17:1031-8, 2007.
9. Khan A, Nose V. Pathology of the thyroid gland. In: Lloyd RV, editors. Endocrine pathology: differential diagnosis and molecular advances. Totowa: Humana Press. pp 159-62, 2004.
10. Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary, thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid. 19:137-141, 2009.
11. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol. 21:296-303, 2009.
12. Kurukahvecioglu O, Taneri F, Yuksel O, et al. Total thyroidecto-my for the treatment of Hashimoto's thyroiditis coexisting with papillary thyroid carcinoma. Adv ther. 24:510-6, 2007.
13. Lewis CM, Chang KP, Pitman M, et al. Thyroid fine-needle aspiration biopsy: variability in reporting. Thyroid. 19:717-23, 2009.
14. Maceri DR, Sullivan MJ, McClatchney KD. Autoimmune thyroiditis: pathophysiology and relationship to thyroid cancer. Laryngoscope. 96:82-6, 1986.
15. Matesa-Anic D, Matesa N, Dabelic N, et al. Coexistence of papillary carcinoma and Hashimoto's thyroiditis. Acta clinica Croatica. 48:9-12, 2009.
16. Oertel YC. Fine-Needle Aspiration in the Evaluation of Thyroid Neoplasms. Endocr pathol. 8:215-24, 1997.
17. Okayasu I, Fujiwara M, Hara Y, et al. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans. Cancer. 76:2312-18, 1995.
18. Oliveira AM, Hsi BL, Weremowicz S, et al. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res. 64:1920-23, 2004.
19. Pisanu A, Piu S, Cois A, et al. Coexisting Hashimoto's thyroiditis with differentiated thyroid cancer and benign thyroid diseases: indications for thyroidectomy. Chir Ital. 55:365-72, 2003.
20. Prasad ML, Huang Y, Pellegata NS, et al. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology. 45:39-46, 2004.
21. Pu RT, Yang J, Wasserman PG, et al. Does Hurthle cell lesion/ neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol. 34:330-4, 2006.
22. Repplinger D, Bargren A, Zhang YW, et al. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 150:49-52, 2008.
23. Rhoden KJ, Unger K, Salvatore G, et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab. 91:2414-23, 2006.
24. Richardson DS, Gujral TS, Peng S, et al. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins. Cancer Res. 69:4861-69, 2009.
25. Sargent R, LiVolsi V, Murphy J, et al. BRAF mutation is unusual in chronic lymphocytic thyroiditis-associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis. Endocr pathol. 17:235-41, 2006.
26. Schittenhelm MM, Kollmannsberger C, Oechsle K, et al. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Molecular cancer therapeutics. 8:481-9, 2009.
27. Schmidt J, Derr V, Heinrich MC, et al. BRAF in papillary thyroid carcinoma of ovary (struma ovarii). Am J Surg Pathol, 31:1337-43, 2007.
28. Sheils OM, O'Eary JJ, Uhlmann V, et al. ret/PTC-1 Activation in Hashimoto Thyroiditis. Int J Surg Pathol, 8:185-9, 2000.
29. Shih ML, Lee JA, Hsieh CB, et al. Thyroidectomy for Hashimoto's thyroiditis: complications and associated cancers. Thyroid. 18:729-34, 2008.
30. Tee YY, Lowe AJ, Brand CA, et al. Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review. Ann Surg. 246:714-20, 2007.
31. Trovisco V, Soares P, Preto A, et al. Molecular genetics of papillary thyroid carcinoma: great expectations. Arq Bras Endo-crinol Metabol. 51:643-53, 2007.
32. Tyner JW, Erickson H, Deininger MW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 113:1749-55, 2009.
33. Vasko V, Ferrand M, Di Cristofaro J, et al. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab, 88:2745-52, 2003.
34. Weber D, Brainard J, Chen L. Atypical epithelial cells, cannot exclude papillary carcinoma, in fine needle aspiration of the thyroid. Acta Cytol. 52:320-4, 2008.
35. Wirtschafter A, Schmidt R, Rosen D, et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope. 107:95-100, 1997.